Speakers at the CVS meeting in Florida last week spoke about the utility and effectiveness of sequencing approaches in the study of viruses.
The firm recently made strategic hires with commercialization experience in anticipation of bringing its handheld point-of-care device to market.
The company said sales of its XT-8 molecular diagnostics system were strong, despite a lighter-than-expected flu season.
The state department has implemented WGS protocols for influenza A and B to track drug resistance and to better understand how the virus changes from year to year.
Researchers discussed using WGS to predict antibacterial resistance, to inform influenza vaccine development, and to diagnose and build drug resistance profiles for tuberculosis.
In PLOS this week: role of fibrillarin during henipavirus infection, ancestry patterns in Bene Israel individuals, and more.
The firm's preliminary revenues were lower than expected and led to analyst downgrades and a drop in early trade.
Researchers sequenced seven dozen flu patients to characterize viral genetic diversity and examine viral transmission.
The bank downgraded Quidel's shares to market perform and trimmed its Q4 revenue forecast due to a mild flu season.
The test is the first of several planned CLIA-waived assays from Cepheid, and the first point-of-care test on the market to differentiate flu from RSV.
A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.
The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.
Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.